Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Marchpole Update

23 Mar 2005 07:00

Marchpole Holdings PLC23 March 2005 23 March 2005 Marchpole Holdings plc ("the Company") Marchpole Update Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ("JCC") and Jean-Charles de Castelbajac / Rossignol,Emmanuel Ungaro and Ungaro. The Company is pleased to announce that its differences with Ozwald Boateng andhis company have been resolved by the current court proceedings and aninjunction has been granted preventing Bespoke Couture Limited from sellingsuits and other items through a discount outlet, established without referenceto the Company. The dispute involved a number of issues. In April 2004 Ozwald Boateng andBespoke Couture alleged breach of contract and threatened termination of itsdiffusion licence with the Company. The allegation was made in respect of theCompany withholding a compensation payment under an agreement first made inOctober 2002 that provided for the termination or conclusion of an O-Z designagreement with Debenhams and subsequent removal of O-Z stock, which the Companyalleged was to take place by 1 September 2003. This agreement was concludedseparately to the main licence contract. As stock did exist at this time theCompany withheld payments and sought an amicable conclusion. Under threat ofcourt proceedings Bespoke Couture withdrew its first threat to terminate andwhen a second threat was made this was successfully resisted with BespokeCouture having to withdraw its threat and costs were awarded to the Company.Following recent court proceedings it was found that the Company should make thecompensation payment from March 2004, the date that the O-Z product was finallyremoved from Debenhams, a position which the Company has always been prepared toconsider. During November 2004, the Company became aware of an Ozwald Boateng discountoutlet operating at Bicester Village. the Company contended that this was inbreach of the main licence agreement and this was confirmed by yesterday'sjudgment. The injunction granted, as Bespoke Couture has accepted, will meanthat Bespoke Couture will have to close this outlet. Costs were awarded reflecting success on the various issues with the detailedfinancial implications to be determined at a later date. Greg Tufnell, Chief Executive commented: "Throughout this process we have always sought to reassure our shareholders thatthese issues would not impact our main licence agreement nor our financialprojections. The judgment handed down is consistent with these reassurances andI now look forward to focusing on the successful platform Marchpole has builtfor the Boateng brand" For further information contact: Marchpole Greg Tufnell - Chief Executive 020 7908 7700Michael Morris - Executive Director Shore Capital Alex Borrelli 020 7408 4090 Buchanan Tim Thompson / Nicola Cronk 020 7466 5000 Notes to editors: In September this year, Marchpole announced strong interim results for the sixmonths ended 2 October 2004, with operating profit up 194% to £2.6 million(2003: £0.9m) on increased turnover of £15.7 million (2003 : £8.0 million). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.